Filing Flows › Upstream Bio (UPB) › Recalls, complaints & regulation
Upstream Bio (UPB): clinical trials
Upstream Bio (UPB) beyond its filings: 2 active clinical trials.
Upstream Bio's latest quarter
Upstream Bio, Q2 2026: revenue $773K (-18% year over year), net loss $39.7M, operating cash flow −$35.6M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Upstream Bio have?
2 active studies on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.